Enzene Biosciences Ltd

CDMO is so yesterday. Your molecule deserves more. Meet Andy, Shakti, and Enzo as they introduce CIDMO™—Enzene's innovative approach to biologics development that's changing how molecules move from idea to impact. 🎥 Watch the video to see why it's time to think beyond CDMO. Think CIDMO™. #CIDMO #WeAreEnzene

Experience Innovation, Up Close. Schedule a Site Visit. Step inside Enzene's U.S. facility in Hopewell, New Jersey, and discover how we're helping biotech innovators accelerate biologics development through scientific expertise, responsive collaboration, and integrated development and manufacturing capabilities. See our teams, technologies, and commitment to innovation in action. Schedule a visit: https://us.enzene.com/ #CIDMO Norm Stoffregen

It's Biotech Trivia time! 🧪 In 1987, one approval changed biomanufacturing forever. A recombinant protein produced in CHO cells for the first time at commercial scale proved that mammalian cell culture could deliver a medicine to patients. Every mAb you know came after that moment. Can you guess which protein it was? Vote in the poll below. We reveal the answer in the comments in 1 week. 👇

Most antibodies retire after one kill. This one does not. A conventional monoclonal antibody binds its target antigen, gets internalised by the cell, and is degraded along with the antigen it captured. The antibody that cleared the target is gone along with it. A sweeping antibody is engineered to escape that fate. The mechanism is pH-dependent binding. At neutral pH in the bloodstream, the antibody binds its target with high affinity. When the complex is internalised into the endosome, the pH drops. The antibody releases the antigen. FcRn — the neonatal Fc receptor — recycles the antibody back to the cell surface. The antigen is degraded. The antibody is released back into circulation and binds again. The engineering precision required is considerable. Bind too weakly at pH 7.4 and you lose efficacy. Release too slowly at pH 6.0, and the antibody cannot reset. The window between those two failure modes is where the entire therapeutic value of the format lives. For patients living with diseases driven by chronically elevated antigens — where conventional antibodies are cleared before they can make a lasting difference — a molecule that keeps working changes what treatment can look like. #EnzeneExplains #SweepingAntibodies

What if increasing biologics production didn't require a larger manufacturing facility? As biologics manufacturing becomes more localized, the industry needs platforms that are easier to deploy, scale, and operate. The EnzeneX® platform, powered by Fully-Connected Continuous Manufacturing™ (FCCM™) technology, is designed to deliver high productivity in a compact footprint while helping reduce manufacturing costs and capital requirements. Watch our CEO, Himanshu Gadgil, PhD, explain why the future of biologics manufacturing may not be bigger—but smarter.

Meet Andy, Shakti, and Enzo. Inspired by the people behind Enzene, these characters represent the values that shape every interaction, every decision, and every partnership. Through their stories, you'll get a glimpse of what it's like to work with us—from Pune to New Jersey. Because great CIDMO™ (Continuously Innovative Development and Manufacturing Organization) partnerships aren't built on capabilities alone, they're built on candor, excellence, entrepreneurship, integrity, innovation, and respect. This is our culture. This is our community. We Are Enzene. #WeAreEnzene

We are hiring! Interested candidates can apply through the post below. #hiring

When a bispecific molecule doesn't meet manufacturing expectations, the process—not the molecule—often needs to change. See how Enzene applied its Fully-Connected Continuous Manufacturing™ (FCCM™) technology to optimize process performance and create a scalable manufacturing solution. Explore the full case study below:

We're growing our team in Pune and looking for passionate professionals to join us. If you're eager to work with cutting-edge biologics technologies, contribute to advancing healthcare, and build your career in a culture driven by Passion. Innovation. Life., we'd love to hear from you. 👉 Explore current openings & apply: Visit the Careers page on the Enzene website: https://lnkd.in/d9z9MqhN #JobsAtEnzene #hiring #IndiaJobs #CDMO

Every production cell line has its strengths—but selecting the right one is always a balancing act. If you could prioritize just one factor, which would it be? Cast your vote and tell us why in the comments. We're curious to see how perspectives differ across R&D, process development, manufacturing, and quality teams. #CelllineEngineering #CellLineDevelopment